MetaCap

Fate Therapeutics (FATE) vs Outlook Therapeutics (OTLK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fate Therapeutics (FATE) has outperformed Outlook Therapeutics (OTLK) over the past year, losing 10.8% versus a loss of 79.3%. Over five years, FATE leads with a -98.3% price change compared with -98.6% for OTLK. Fate Therapeutics is the larger company by market cap ($111.8 million vs $94.9 million), about 1.2 times the size.

Fate Therapeutics converts more of its revenue into profit, with a net margin of -2051.1% versus -4416.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FATE-10.78%OTLK-79.26%
+217%+56%-104%
Nov 21, 20251 yearNov 20, 2026
FATE-98.36%OTLK-98.73%
+37%-34%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FATE versus OTLK key metrics
MetricFATEOTLK
Share price$0.919$0.39
Market cap$111.82M$94.94M
1-day change-9.01%-2.74%
YTD return-6.22%-75.32%
1-year return-10.78%-79.26%
5-year return-98.25%-98.58%
EPS (TTM)$-1.03$-0.70
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.65M$1.41M
Revenue growth (YoY)-51.24%—
Net income (latest FY)$-136.31M$-62.42M
Gross margin—4.05%
Operating margin-2222.45%-4744.25%
Net margin-2051.08%-4416.22%
52-week high$3.23$2.54
52-week low$0.90$0.161
Distance from 52-week high-71.55%-84.63%
Analyst consensusbuynone
Avg. price target upside+522.42%+1189.74%
Average volume1.53M4.60M
Shares outstanding121.67M243.45M
Employees16117
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FATE has outperformed OTLK by 68.5 percentage points over the past year.
  • Fate Therapeutics is more profitable, keeping -2051.1 cents of every revenue dollar as net income versus -4416.2 cents for Outlook Therapeutics.

About Fate Therapeutics

FATE stock →

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees

About Outlook Therapeutics

OTLK stock →

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees

FATE vs OTLK FAQ

Which is bigger, Fate Therapeutics or Outlook Therapeutics?

Fate Therapeutics (FATE) is larger, with a market capitalization of $111.82M compared with $94.94M for Outlook Therapeutics (OTLK).

Which stock has performed better over the past year, FATE or OTLK?

FATE returned -10.78% over the past 12 months, compared with -79.26% for OTLK (price return, excluding dividends). Past performance does not predict future results.

Are Fate Therapeutics and Outlook Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons